MIRACLE FRUIT SEED OIL TREATMENT

A new formulation for hair featuring Miracle Fruit Seed Oil (MFSO) is intended to naturally moisturize, condition, detangle, strengthens, nourish, protect and restore hair. Miracle Fruit Seed Oil Hair Treatment has been clinically studied and shown to support a 200 percent Increase in the Healthy Hair Index. Use of the product significantly reduced hair loss due to breakage and repaired split ends. It also protected and reversed hair from damage caused by chemicals, physical agents, pollution, heat, and UV rays, the manufacturer says. The product retails for $50 and is available online. miraclefruitoil.com

NEW DERMATOLOGIC SURGERY TEXTBOOK FROM MCGRAW-HILL

McGraw-Hill has just released Jonathan Kantor MD’s new 1,440-page textbook, Dermatologic Surgery, the most comprehensive and richly illustrated dermatologic surgery textbook ever published, and the first new major multimedia textbook in the field in 13 years. With section editors including Drs. John Albertini, Jeremy Bordeaux, Leonard Dzubow, Naomi Lawrence, and Stanley Miller, this new first-of-its-kind text bridges a general dermatologic surgery textbook and a specialized flap reference book. The text includes 81 chapters addressing the full range of reconstructive and cosmetic dermatologic surgery, and includes numerous first-in-class features such as chapter-opener structured summaries with illustrations, hundreds of pages on Mohs surgery, over 400 pages of flap repairs, and chapters based both on flap classification and regional repair approaches to improve the experience for novices and experts alike.

The book includes over 3,000 photos and professional medical illustrations and more than 12 hours of video.

REVISION INTRODUCES NEW PATIENT-FRIENDLY OPTION

Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of women who depend on professionals for anti-aging solutions ranging from powerful in-office treatments to customized at-home regimens. All regimens are designed to take the guesswork out of caring for skin when addressing the visible signs of aging.

Revision introduces a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of women who depend on professionals for anti-aging solutions ranging from powerful in-office treatments to customized at-home regimens. All regimens are designed to take the guesswork out of caring for skin when addressing the visible signs of aging.

Plus, the trial regimens are travel-friendly, featuring TSA approved sizes and a complimentary travel bag. As a bonus, each set includes an online redeemable code for a free full-size anti-aging moisturizer. The kits are available exclusively at authorized skincare professionals’ offices. RevisionSkincare.com.

SENTÉ LAUNCHES ILLUMINÉ EYE CREAM

SENTÉ Illuminé Eye Cream to help diminish the appearance of redness and periorbital discoloration is now available. The formulation also improves the appearance of wrinkles and crepiness, as well as the appearance of puffiness, the company says. In a clinical study, 93 percent of subjects agreed that SENTÉ® Illuminé Eye Cream improved the appearance of dark circles and left their skin feeling hydrated. Sente reports. Nearly three-quarters of subjects agreed that the eye cream improved the appearance of under-eye puffiness. The product contains patented Heparan Sulfate Analog (HSA) technology to improves the appearance of the skin around the eye as early as two weeks, according to the company. sentelabs.com
BIOTIN SUPPLEMENTS CAUSE MISLEADING TEST RESULTS

A new case report in the *Journal of the Endocrine Society* documents how a patient’s use of a biotin supplement caused her to have clinically misleading test results, which prompted numerous consultations and unnecessary radiographic and laboratory testing.

In November 2017, the FDA issued a warning “alerting the public, healthcare providers, lab personnel, and lab test developers that biotin can significantly interfere with certain lab tests and cause incorrect test results which may go undetected.”

The patient in the case report took a 5,000mcg dose of biotin daily. Biotin supplements in that dosage are commonly sold over-the-counter, without a prescription, in many grocery and drug stores for about $8-$20 a bottle.

In this patient’s case, “The negative clinical impact included weeks of psychological distress concerning the possibilities of hypercortisolemia or a testosterone-producing tumor. Most significantly, these abnormal test results nearly resulted in an unnecessary invasive procedure for a complex patient with a hypercoagulable state,” the case report says.

“The literature is lacking with regard to biotin interference with serum cortisol and testosterone immunoassays, as in our case-report,” says Maya Styner, MD, associate professor of endocrinology and metabolism in the department of medicine and the case report’s corresponding author.

“Patients are ingesting supplements in a higher frequency, and higher doses, and therefore this case is timely and relevant from both a clinical and basic-science perspective.”

STUDY EVALUATES TOPICAL 2% TOFACITINIB FOR CHILDREN WITH ALOPECIA AREATA AND MORE

Noting a lack of FDA approved treatments for children with alopecia areata (AA) and a lack of large controlled studies on medications used for alopecia totalis (AT) and alopecia universalis (AU), researchers evaluated the efficacy of topical 2% tofacitinib for children with AA, AT, and AU. Clinical trials have shown benefit from oral Janus kinase (JAK) inhibitors in adults with AA, but data regarding pediatric patients are limited to case reports, the authors note.

Eleven pediatric patients aged four to 16 whose alopecia had been present at least two years and who had failed treatment with three-week courses of oral prednisone or prednisolone as well as class 1 or 2 topical steroids were treated with nonpatented formulations of 2% topical tofacitinib.
The results, published in the *Journal of the American Academy of Dermatology*, found the average change in Severity of Alopecia Tool (SALT) score was a reduction of 32.3 percent. Eight of 11 patients demonstrated an improvement in SALT score and three had cosmetically acceptable regrowth, meaning it was sufficient to cover the scalp or able to conceal residual areas of hair loss. All patients tolerated treatment without adverse effects.

According to the study, the limited results suggest topical tofacitinib might be a reasonable adjunct or second-line therapy for pediatric patients with AA, AT, and AU for whom systemic therapies are not desired. More studies are needed.

**SB208 INCREASES DAILY NAIL GROWTH RATE OVER FOUR WEEKS OF TREATMENT**

Novan, Inc. shared data from its onychomycosis development program with SB208 gel demonstrating an enhanced nail growth rate in adult females at last month’s International Investigative Dermatology meeting in Orlando, FL.

In the Phase 1, single-center, double-blinded, randomized clinical trial in 32 adult females, Novan evaluated the rate of fingernail growth associated with SB208 16% and the local tolerability of the gel when used over the course of 29 days. The daily nail growth rate of each patient was assessed first during a 28-day run-in period with no treatment and then a 28-day period with once daily topical treatments of SB208 16% or vehicle. SB208 16% demonstrated a statistically significant greater mean daily nail growth rate for the treatment period when compared to the same patient’s own growth rate in the run-in period, as well as versus vehicle-treated patients during the treatment period. SB208 16% was well tolerated and no adverse events related to use were reported.

“Fungal infections like onychomycosis of the toenails can be difficult to treat due to slow growth of the nails,” stated Boni Elewski, MD, endowed professor for graduate education and chair; residency program director, Department of Dermatology at the University of Alabama, Birmingham. “SB208’s ability to kill the dermatophytes that cause onychomycosis and tinea pedis while accelerating nail growth via nitric oxide could provide a meaningful advancement in an otherwise year-long course of treatment for patients with onychomycosis.”

Novan previously announced positive Phase 2 clinical trial results with SB208 in patients with tinea pedis caused by the same pathogen that is prominent in onychomycosis. The Company is currently exploring potential partnerships, collaborations or other strategic relationships to further advance SB208 in the US and select geographies.